HyperlipidemiaREDUCE-LipidNCT07311941
Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event
An observational study of Hyperlipidemia and Cardio Vascular Disease, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD). Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hyperlipidemia, Cardio Vascular Disease
- How many people
- 1,000 participants
- Where
- 1 siteHong Kong
- Study dates
- 30 Dec 2024to 30 Jun 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged greater than 18 and who are admitted for a diagnosis of acute coronary syndrome (ACS) due to atherosclerotic coronary artery disease based on invasive coronary angiography will be recruited into this registry.
Who may be able to join
- Age >18
- (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease
- (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease
Who cannot join
- Inability to provide valid consent by the patient or his legal guardian
- Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease.
- Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy < 6 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
Prince of Wales Hospital
Shatin, New Terrritories, 999077
About this study
Official title: Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).
Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain.
This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.
- Conditions
- Hyperlipidemia, Cardio Vascular Disease
- Medical subject headings
- Hyperlipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Acute Coronary Syndrome | Patient with acute coronary syndrome due to atherosclerotic coronary artery disease | |
| Chronic coronary syndrome | Patient with chronic coronary syndrome due to atherosclerotic coronary artery disease |
What is being measured
The primary outcome is the main question the study is designed to answer.
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at baseline
Measured: Baseline
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 8
Measured: week 8
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 26
Measured: Week 26
Low-density lipoprotein cholesterol (LDL-C) level
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 52
Measured: Week 52
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at Baseline
Measured: Baseline
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 8
Measured: Week 8
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 26
Measured: Week 26
Low-density lipoprotein cholesterol (LDL-C) level
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 52
Measured: Week 52
Secondary outcomes (16)
Rate of subject meeting LDL-C target
Proportion of patients meeting prespecified LDL-C goals (>50% reduction from baseline) at week 26.
Measured: Week 26
Rate of subject meeting LDL-C target
Proportion of patients meeting prespecified LDL-C goals (<1.4mmol/l) at week 26.
Measured: Week 26
Rate of subject meeting LDL-C target
Proportion of patients meeting prespecified LDL-C goals (<1.8mmol/L) at week 26.
Measured: Week 26
12-Item Short Form Survey (SF-12)
Patient's quality of life as measured by SF-12 at baseline
Measured: Baseline
12-Item Short Form Survey (SF-12)
Patient's quality of life as measured by SF-12 at week 8
Measured: Week 8
12-Item Short Form Survey (SF-12)
Patient's quality of life as measured by SF-12 at week 26
Measured: Week 26
12-Item Short Form Survey (SF-12)
Patient's quality of life as measured by SF-12 at week 52
Measured: Week 52
Rate of major adverse cardiovascular event (MACE)
Occurrence of any major adverse cardiovascular event (MACE) at Baseline
Measured: Baseline
Rate of major adverse cardiovascular event (MACE)
Occurrence of any major adverse cardiovascular event (MACE) at week 8
Measured: Week 8
Rate of major adverse cardiovascular event (MACE)
Occurrence of any major adverse cardiovascular event (MACE) at week 26
Measured: Week 26
Rate of major adverse cardiovascular event (MACE)
Occurrence of any major adverse cardiovascular event (MACE) at week 52
Measured: Week52
Modification of lipid lowering therapy (LLT)
Modification of lipid lowering therapy (LLT) at week 8
Measured: Week 8
Modification of lipid lowering therapy (LLT)
Modification of lipid lowering therapy (LLT) at week 26
Measured: Week 26
Modification of lipid lowering therapy (LLT)
Modification of lipid lowering therapy (LLT) at week 52
Measured: Week 52
Lipid Lowering Therapy adherence
LLT adherence, expressed in proportion of days covered, at week 52
Measured: Week 52
Tolerability of Lipid Lowering Therapy
Rate of adverse drug event reported by subjects on lipid lowering therapy at week 52
Measured: Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2025
- Study start30 Dec 2024
- Primary completion31 Dec 2030 (estimated)
- Study completion30 Jun 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HyperlipidemiaStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, GuangMing Tan, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07311941
- Sponsor's protocol ID
- 2024.356
- Acronym
- REDUCE-Lipid
- Status last verified
- Dec 2025
- First submitted
- 17 Dec 2025
- Last updated
- 31 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study
- ClinicalTrials.gov ID
- NCT07311941
- Acronym / sponsor ID
- REDUCE-Lipid / 2024.356
- Conditions
- Hyperlipidemia, Cardio Vascular Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 30 Dec 2024 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 30 Jun 2031 (estimated)
- First posted
- 31 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).
Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain.
This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Acute Coronary Syndrome | – | –Patient with acute coronary syndrome due to atherosclerotic coronary artery disease |
| Chronic coronary syndrome | – | –Patient with chronic coronary syndrome due to atherosclerotic coronary artery disease |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged greater than 18 and who are admitted for a diagnosis of acute coronary syndrome (ACS) due to atherosclerotic coronary artery disease based on invasive coronary angiography will be recruited into this registry.
Key inclusion criteria (3 listed)
- Age >18
- (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease
- (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease
Key exclusion criteria (3 listed)
- Inability to provide valid consent by the patient or his legal guardian
- Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease.
- Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy < 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Low-density lipoprotein cholesterol (LDL-C) level
Time frame: Baseline
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at baseline
Low-density lipoprotein cholesterol (LDL-C) level
Time frame: week 8
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 8
Low-density lipoprotein cholesterol (LDL-C) level
Time frame: Week 26
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 26
Low-density lipoprotein cholesterol (LDL-C) level
Time frame: Week 52
Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 52
Low-density lipoprotein cholesterol (LDL-C) level
Time frame: Baseline
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at Baseline
Low-density lipoprotein cholesterol (LDL-C) level
Time frame: Week 8
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 8
Low-density lipoprotein cholesterol (LDL-C) level
Time frame: Week 26
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 26
Low-density lipoprotein cholesterol (LDL-C) level
Time frame: Week 52
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 52
16 secondary outcomes
Rate of subject meeting LDL-C target
Time frame: Week 26
Rate of subject meeting LDL-C target
Time frame: Week 26
Rate of subject meeting LDL-C target
Time frame: Week 26
12-Item Short Form Survey (SF-12)
Time frame: Baseline
12-Item Short Form Survey (SF-12)
Time frame: Week 8
12-Item Short Form Survey (SF-12)
Time frame: Week 26
12-Item Short Form Survey (SF-12)
Time frame: Week 52
Rate of major adverse cardiovascular event (MACE)
Time frame: Baseline
Rate of major adverse cardiovascular event (MACE)
Time frame: Week 8
Rate of major adverse cardiovascular event (MACE)
Time frame: Week 26
Rate of major adverse cardiovascular event (MACE)
Time frame: Week52
Modification of lipid lowering therapy (LLT)
Time frame: Week 8
Modification of lipid lowering therapy (LLT)
Time frame: Week 26
Modification of lipid lowering therapy (LLT)
Time frame: Week 52
Lipid Lowering Therapy adherence
Time frame: Week 52
Tolerability of Lipid Lowering Therapy
Time frame: Week 52
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Hyperlipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Active, not recruitingObservational study
Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)
Familial Hypercholesterolaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hyperlipidemia and Cardio Vascular Disease, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Guangming Tan (852-35051518, xjldaniel@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Low-density lipoprotein cholesterol (LDL-C) level (time frame: Baseline). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2025.